**Core Concept**
Malignant hyperthermia (MH) is a life-threatening complication that can occur in response to certain anesthetic agents, particularly volatile inhalational anesthetics and succinylcholine. It is characterized by muscle rigidity, hypermetabolism, and a rise in body temperature.

**Why the Correct Answer is Right**
The administration of succinylcholine in this patient, particularly in the context of an inhalational anesthetic, is likely to trigger a malignant hyperthermia crisis. Succinylcholine can cause a significant release of calcium ions from the sarcoplasmic reticulum, leading to muscle rigidity and hypermetabolism. The dark red urine is likely due to myoglobinuria, which is a common finding in MH. The correct treatment involves stopping the anesthetic agents, administering dantrolene to block calcium release from the sarcoplasmic reticulum, and providing supportive care, including cooling the patient and managing cardiovascular instability.

**Why Each Wrong Option is Incorrect**
**Option A:** **Naloxone** is an opioid antagonist and would not be effective in treating malignant hyperthermia.
**Option B:** **Phentolamine** is an alpha-adrenergic blocker and is used to treat hypertension, but it is not the primary treatment for malignant hyperthermia.
**Option C:** **Succinylcholine** is the likely culprit in triggering the malignant hyperthermia crisis, so administering more succinylcholine would be counterproductive.

**Clinical Pearl / High-Yield Fact**
Malignant hyperthermia is a medical emergency that requires prompt recognition and treatment. The diagnosis is often made clinically, based on the patient's response to anesthetic agents, and should be suspected in any patient who develops muscle rigidity, fever, or tachycardia during anesthesia.

**Correct Answer:** C. Dantrolene is the primary treatment for malignant hyperthermia, as it blocks calcium release from the sarcoplasmic reticulum and helps to reduce muscle rigidity and hypermetabolism.